초록

The invention relates to antibodies, antibody fragments and binding agents that specifically recognize oligomeric tau but do not bind to monomeric tau, fibrillar tau or non-disease associated forms of tau.

대표청구항 ▼

1. A method of inhibiting the aggregation of tau, the method comprising contacting a composition that comprises tau oligomers with a binding molecule that comprises amino acid sequence SEQ ID NO:1, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:19. 2. The method of

1. A method of inhibiting the aggregation of tau, the method comprising contacting a composition that comprises tau oligomers with a binding molecule that comprises amino acid sequence SEQ ID NO:1, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:19. 2. The method of claim 1, wherein said aggregation of tau is in a cell. 3. The method of claim 1, wherein said aggregation of tau is in brain tissue. 4. The method of claim 1, wherein the tau oligomers are dimeric or trimeric tau. 5. The method of claim 4, wherein the tau oligomers are trimeric tau. 6. The method of claim 4, wherein the tau oligomers are soluble. 7. The method of claim 1, wherein the binding molecule hinds to oligomeric tau and does not bind monomeric tau, fibrillary tau or non-disease associated forms of tau. 8. A method of detecting the presence of tau in a physiological sample, the method comprising contacting a physiological sample with a binding molecule comprising amino acid sequence SEQ ID NO:1, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:19; anddetermining the binding of the binding molecule with said physiological sample wherein binding of the binding molecule to said physiological sample is indicative of the presence of tau oligomers in said physiological sample, wherein said presence of said tau oligomers is indicative of early stage Alzheimer's disease (AD), frontotemporal dementia, other tauopathies, or neurodegeneration following traumatic brain injury. 9. The method of claim 8, wherein the physiological sample brain tissue, serum, cerebrospinal fluid (CSF), blood, urine or saliva. 10. A method of inhibiting the aggregation of tau, the method comprising contacting a composition that comprises tau oligomers with a binding molecule that comprises at least 80% sequence identity to amino acid sequence SEQ ID NO:1. 11. The method of claim 10, wherein said aggregation of tau is in a cell. 12. The method of claim 10, wherein said aggregation of tau is in brain tissue. 13. The method of claim 10, wherein the tau oligomers are dimeric or trimeric tau. 14. The method of claim 13, wherein the tau oligomers are trimeric tau. 15. The method of claim 13, wherein the tau oligomers are soluble. 16. The method of claim 10, wherein the binding molecule binds to oligomeric tau and does not bind monomeric tau, fibrillary tau or non-disease associated forms of tau. 17. A method of inhibiting the accumulation of tau in the brain of a mammal, the method comprising administering to said mammal a composition comprising an antibody fragment or a binding molecule comprising amino acid sequence SEQ ID NO:1, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, or SEQ ID NO:19. 18. The method of claim 17, wherein the binding molecule binds to oligomeric tau and does not bind monomeric tau, fibrillary tau or non-disease associated forms of tau.